New vaccine combo aims to supercharge immune system against HPV-Linked throat cancer

NCT ID NCT05799144

First seen Nov 01, 2025 · Last updated Feb 28, 2026 · Updated 16 times

Summary

This study is testing whether adding two investigational vaccines to a standard immunotherapy drug (pembrolizumab) can better control advanced throat cancer linked to HPV. The vaccines aim to train the immune system to specifically recognize and attack cancer cells. The trial is for adults whose cancer has returned or spread and who have not yet received treatment for their advanced disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC OROPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Alabama Birmingham

    RECRUITING

    Birmingham, Alabama, 35249, United States

    Contact

    Contact

  • Vanderbilt University/Ingram Cancer Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.